Clear ×
Acurx Pharmaceuticals, Inc. ACXP

Showing 10-K, 10-Q & 8-K from the last 6 months. Need full history or all form types?

Apr 16, 2026 8-K 9 signals fired
Other
Corporate Organization And Standing Representation Market Price Definition Institutional Investment Ipo Or Capital Raising Completion Form S3 Shelf Registration Disclosure Warrant Exercise Share Delivery Ipo Net Proceeds Disclosure
Core
Lead Asset Progress Indication Expansion
Mar 12, 2026 10-K 58 signals fired · top 15
Other
Warrant Valued Black Scholes Reverse Stock Split Effected Ipo Or Capital Raising Completion Committee Meeting Attendance Disclosure Classified Board Director Election Executive Educational Background Disclosure Personnel Cost Decrease Disclosure Nasdaq Minimum Bid Price Delisting Notice Financing Activities Cash Flow Disclosure Institutional Investment Patent Family Portfolio Disclosure Net Loss Reported Cybersecurity Risk Management Program Disclosure Audit Committee Preapproval Policy
Core
Clinical Trial Result
Mar 9, 2026 8-K 26 signals fired · top 15
Other
Fast Track Designation Received Fast Track Granted Earnings Call Replay Details Orphan Status Granted Non Employee Director Compensation Disclosed Enrollment Ahead Of Schedule Patient Retention High Expanded Access Program Active Breakthrough Therapy Granted Interim Data Positive
Core
Clinical Trial Result Regulatory Designation Only Lead Asset Progress Patient Enrollment Velocity
Biotech Risk
Orphan Drug Designation
Nov 12, 2025 10-Q 17 signals fired · top 15
Other
Financing Activities Cash Flow Disclosure Net Loss Reported Personnel Cost Decrease Disclosure Reverse Stock Split Effected Nasdaq Minimum Bid Price Delisting Notice Ipo Or Capital Raising Completion Equity Plan Share Reserve Disclosure Nyse Listing Disclosure Cybersecurity Breach Reputational Harm Disclosure Equity Plan Board Approval Conditional On Shareholder Vote Administrative Efficiency Shares Outstanding Disclosure Stock Option Grant Disclosed Institutional Investment
Core
Indication Expansion